Literature DB >> 31255887

Analysis of the frequencies and functions of CD4+CD25+CD127low/neg, CD4+HLA-G+, and CD8+HLA-G+ regulatory T cells in pre-eclampsia.

Maryam Zare1, Bahia Namavar Jahromi2, Behrouz Gharesi-Fard3.   

Abstract

Most of the investigations on regulatory T cells (Treg) have focused on CD4+CD25+Foxp3+ Treg cells. Although new subsets of these cells such as CD4+CD25+CD127low/neg, CD4+HLA-G+, and CD8+HLA-G+ Treg cells have been introduced, documents regarding these populations are limited or controversial in case of pregnancy and pre-eclampsia (PE). Here, we investigated the frequencies of the three aforementioned Treg cell subsets in the peripheral blood of non-pregnant (n = 15), healthy pregnant, and preeclamptic women (n = 17 in each group) using flow cytometry. We also assessed the ability of the isolated CD4+CD25+CD127low/neg and CD4+HLA-G+ Treg cells to suppress responder T cells proliferation and cytokine secretion using CFSE dye dilution and ELISA technique. Our results showed that the frequency of CD4+CD25+CD127low/neg Treg cells was significantly lower in preeclamptic women (p =  0.001). Also, this subset negatively correlated with both systolic (R= - 0.401, p =  0.004) and diastolic (R= - 0.541, p =  0.001) blood pressures. Regarding CD4+HLA-G+ and CD8+HLA-G+ Treg cells, the mean percentages of these cells were significantly higher in the context of normal pregnancy (p <  0.01). Finally, our results in the functional assay experiments did not show statistically significant differences between groups (p ≥  0.05), but they reveal a shift toward the lower suppressive capacity of CD4+CD25+CD127low/neg and CD4+HLA-G+ Treg cells in preeclamptic patients which might be clinically important. In conclusion, a significant decrease in the frequency of Treg cell subsets and also a shift toward the lower suppressive capacity of these cells in preeclamptic patients may lead to immunological maladaptation in the context of PE.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD4(+)CD25(+)CD127(low/neg) regulatory T cells; CD4(+)HLA-G(+) regulatory T cells; CD8(+)HLA-G(+) regulatory T cells; Pre-eclampsia; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 31255887     DOI: 10.1016/j.jri.2019.06.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

Review 1.  Cellular immune responses in the pathophysiology of preeclampsia.

Authors:  Derek Miller; Kenichiro Motomura; Jose Galaz; Meyer Gershater; Eun D Lee; Roberto Romero; Nardhy Gomez-Lopez
Journal:  J Leukoc Biol       Date:  2021-04-13       Impact factor: 6.011

2.  Regulatory T Cells in Pregnancy Adverse Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Samantha Green; Marina Politis; Kathrine S Rallis; Alba Saenz de Villaverde Cortabarria; Athina Efthymiou; Nicoleta Mureanu; Kathryn V Dalrymple; Cristiano Scottà; Giovanna Lombardi; Rachel M Tribe; Kypros H Nicolaides; Panicos Shangaris
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 3.  Update on Immune Mechanisms in Hypertension.

Authors:  Shobana Navaneethabalakrishnan; Hannah L Smith; Cristina M Arenaz; Bethany L Goodlett; Justin G McDermott; Brett M Mitchell
Journal:  Am J Hypertens       Date:  2022-10-03       Impact factor: 3.080

Review 4.  Regulatory T Cells in Pregnancy: It Is Not All About FoxP3.

Authors:  Juliette Krop; Sebastiaan Heidt; Frans H J Claas; Michael Eikmans
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 5.  Immune Cells in the Uterine Remodeling: Are They the Target of Endocrine Disrupting Chemicals?

Authors:  Nicole Meyer; Ana Claudia Zenclussen
Journal:  Front Immunol       Date:  2020-02-19       Impact factor: 7.561

6.  Decidualization Process Induces Maternal Monocytes to Tolerogenic IL-10-Producing Dendritic Cells (DC-10).

Authors:  Soledad Gori; Elizabeth Soczewski; Laura Fernández; Esteban Grasso; Lucila Gallino; Fatima Merech; Ana Colado; Mercedes Borge; Claudia Pérez Leirós; Gabriela Salamone; Rosanna Ramhorst
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.